U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H47N5O5S
Molecular Weight 613.811
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of WX-UK1 FREE BASE

SMILES

CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC=CC(=C2)C(N)=N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C

InChI

InChIKey=ISJSHQTWOHGCMM-NDEPHWFRSA-N
InChI=1S/C32H47N5O5S/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34)/t28-/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H47N5O5S
Molecular Weight 613.811
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Wilex developed WX-UK1 as a specific inhibitor of human trypsin-2, human trypsin-3 and urokinase-plasminogen activator. WX-UK1 participated in phase I clinical trial in combination with capecitabine in advanced malignancies to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics. However, in April 2014, the clinical development of this drug was discontinued, as part of a company restructure.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL3159
Sources: DOI: 10.1158/1535-7163.TARG-17-B055
75.0 nM [Ki]
Target ID: CHEMBL4551
Sources: DOI: 10.1158/1535-7163.TARG-17-B055
19.0 nM [Ki]
Target ID: P00749
Gene ID: 5328.0
Gene Symbol: PLAU
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
2013 Mar 5
DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
2015 Mar

Sample Use Guides

Advanced pancreatic adenocarcinoma: 1000 mg m(-2) of gemcitabine IV weekly either alone (arm A) or in combination with 200 mg (arm B) or 400 mg (arm C) oral upamostat daily.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:25:07 UTC 2023
Edited
by admin
on Sat Dec 16 01:25:07 UTC 2023
Record UNII
00LOF6890B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
WX-UK1 FREE BASE
Code English
1-PIPERAZINECARBOXYLIC ACID, 4-((2S)-3-(3-(AMINOIMINOMETHYL)PHENYL)-1-OXO-2-(((2,4,6-TRIS(1-METHYLETHYL)PHENYL)SULFONYL)AMINO)PROPYL)-, ETHYL ESTER
Systematic Name English
Code System Code Type Description
FDA UNII
00LOF6890B
Created by admin on Sat Dec 16 01:25:07 UTC 2023 , Edited by admin on Sat Dec 16 01:25:07 UTC 2023
PRIMARY
PUBCHEM
9895193
Created by admin on Sat Dec 16 01:25:07 UTC 2023 , Edited by admin on Sat Dec 16 01:25:07 UTC 2023
PRIMARY
CAS
220355-63-5
Created by admin on Sat Dec 16 01:25:07 UTC 2023 , Edited by admin on Sat Dec 16 01:25:07 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY